Lung Cancer

The AJMC^® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Heather Wakelee, MD

Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee

September 11th 2024

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Diverse representation in health care materials is one of multiple factors that could benefit patient education initiatives | image credit: Fitry - stock.adobe.come

Different Options for Different People: Dr Bellinda King-Kallimanis Explores the State of Patient Education in Lung Cancer

September 10th 2024

Sandip Patel, MD

Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC

September 6th 2024

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

Late-Stage Vibostolimab, Pembrolizumab Plus Chemotherapy Trial Discontinued Due to Adverse Events

By Julia Bonavitacola

August 8th 2024

AJMC

Shared Decision-Making for Lung Cancer Screening: More Straw for the Camel’s Back

By Jonas B. Green, MD, MPH, MSHS

May 31st 2024

Key Updates in the Management of Small Cell Lung Cancer

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

More News

Image of lung cancer.jpe

July 26th 2023

Risk Prediction Improvements Needed for Former Smokers at High Risk for Lung Cancer

Prediction models are needed to identify individuals at high risk for lung cancer who are former smokers and for whom low-dose computed tomography screening is not recommended, according to one study.

Person on computer | Image credit: BullRun - stock.adobe.com

July 20th 2023

Study Explores Symptoms, Lived Experiences of Patients With NSCLC Using Social Media

Researchers assessed public posts on websites to better understand the experiences of patients with non–small cell lung cancer (NSCLC).

IV_chemo - Sherry Young - stock.adobe.com.jpe

July 17th 2023

PAPILLON Study Meets Clinical End Point in Patients With EGFR Exon 20 Insertion–Mutated Advanced NSCLC

Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

Lungs

July 15th 2023

Study Identifies Which Patients With SCLC May Benefit Most From SRS

Patients with small cell lung cancer (SCLC) with fewer than 5 brain metastases fared better than those with more than 5 when treated with stereotactic radiosurgery (SRS).

lungcancer.jpe

July 12th 2023

Standardized SIF Reporting, Management Guidelines Needed in LDCT Lung Screening

A retrospective case series study suggests that standardized guidelines for reporting and managing significant incidental findings (SIFs) in low-dose computed tomography (LDCT) lung cancer screening could help optimize the treatment of patients whose LDCT scans show SIFs.

Lung cancer, 3D illustration and photo under microscope. Light micrograph showing lung adenocarcinoma: © Dr_Microbe - stock.adobe.com

July 6th 2023

Meta-Analysis Shows Certain Antidepressants May Increase Lung Cancer Risk

Jared Kaltwasser

Investigators found no significant impact on survival, however.

Lung cancer awareness red background with white ribbon, alarm clock and stethoscope: © WindyNight - stock.adobe.com

June 29th 2023

Survey Outlines Lung Cancer Survivors’ Views on Telerehabilitation

The majority of patients had prior experience with telemedicine, but none had experience with telerehabilitation.

Searching for New Solutions in Treating EGFR-Mutant NSCLC

June 27th 2023

Searching for New Solutions in Treating EGFR-Mutant NSCLC

Abstracts were presented in a session on metastatic lung cancer on the final day of the 2023 American Society of Clinical Oncology Annual Meeting.

DNA Test for Cancer Screening

June 22nd 2023

ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening

A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.

TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC

June 16th 2023

TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC

Kristie L. Kahl

The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).

Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC

June 15th 2023

Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

ctDNA Tumor Fraction Retains Strong Prognostic Value for Advanced NSCLC

June 9th 2023

ctDNA Tumor Fraction Retains Strong Prognostic Value for Advanced NSCLC

Alana Hippensteele

High circulating tumor DNA (ctDNA) tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades for non–small cell lung cancer (NSCLC), according to research discussed during a presentation at the American Society of Clinical Oncology Annual Meeting.

Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting

June 9th 2023

Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting

An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.

Smoking Cessation Associated With Increased Survival Among Patients With Lung Cancer

June 2nd 2023

Smoking Cessation Associated With Increased Survival Among Patients With Lung Cancer

Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.

OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023

May 24th 2023

OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.

Doctor, woman with tablet in hands and hologram with medical data, anatomy and lung x ray with overlay. Technology research in healthcare, futuristic and analytics with person and wireless tech: © peopleimages.com - stock.adobe.com

May 22nd 2023

Study Assesses Cost Differences for Robot- vs Video-Assisted Thoracoscopic Surgery in Lung Cancer

Researchers took both the learning curve of the new process and the COVID-19 pandemic into consideration.

May 18th 2023

Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer

Jonathan Kish, PhD, MPH Djibril Liassou, MS John Hartman, PhD Solomon J. Lubinga, PhD Dhruv Chopra, MS Bruce Feinberg, DO

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.

Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC

May 17th 2023

Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)

Human Lung model illness, Lung cancer and lung disease. Generative AI: © Royalty-Free - stock.adobe.com

May 16th 2023

Study Examines Incidence, Risk Factors for ICI-Related Pneumonitis in NSCLC

Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.

Happiness group of people huddle and smiling together: © Rawpixel.com - stock.adobe.com

May 11th 2023

Patients With Advanced Lung Cancer Prioritize Social, Relational Goals Above Treatment Outcomes

Jared Kaltwasser

Just 29% of patients listed a treatment-response goal among their top personal goals.

Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC

May 9th 2023

Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

AJMC

May 1st 2023

Factors Associated With Lung Cancer Risk Factor Documentation

Leah M. Marcotte, MD, MS Sara Khor, MASc David R. Flum, MD, MPH Nkem Akinsoto, MSc Vandna Chaudhari, MHA Douglas E. Wood, MD Danielle C. Lavallee, PharmD, PhD Matthew Triplette, MD, MPH Farhood Farjah, MD, MPH

This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.

Liquid and Tissue Biopsy Can Be Complementary in NSCLC, Says Dr Mark Socinski

April 29th 2023

Liquid and Tissue Biopsy Can Be Complementary in NSCLC, Says Dr Mark Socinski

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC

April 27th 2023

ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

Libtayo

April 21st 2023

Dr Tamta Makharadze Discusses EMPOWER-Lung 3 Data for Frontline Cemiplimab Plus Chemo in Advanced NSCLC

Interview by Mary Caffrey

Final overall survival data were presented at the European Lung Cancer Congress in Copenhagen, Denmark.

CancerCare Tool Kit Aims to Guide Employers in Biomarker Coverage Decisions

April 17th 2023

CancerCare Tool Kit Aims to Guide Employers in Biomarker Coverage Decisions

Interview by Mary Caffrey

Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.

Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC

April 15th 2023

Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC

Conor Killmurray Rose McNulty

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.

Estimated Lung Cancer Screening Rates "Extremely Low" Across Insurance Types

April 14th 2023

Estimated Lung Cancer Screening Rates "Extremely Low" Across Insurance Types

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.

Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC

April 5th 2023

Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC

Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.

Davey B. Daniel, MD, chief medical officer, OneOncology

April 4th 2023

Dr Davey Daniel on the Importance of Biomarker Tests for Patients With Lung Cancer

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.

<1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions